News GT Biopharma, Inc. Euronext Paris

Equities

GTBP

US36254L3087

Market Closed - Euronext Paris Other stock markets 05:30:03 2020-12-24 am EST			5-day change	1st Jan Change
0.55 ^EUR	-86.52%		-96.67%	-99.80%

Jun. 27	GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	MT
Jun. 27	GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GT BIOPHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR GTB-3650, AN NK CELL ENGAGER FOR TREATMENT OF CD33+ LEUKEMIA	Jun. 28	AQ
GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	Jun. 27	MT
GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	Jun. 27	DJ
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia	Jun. 27	AQ
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia	Jun. 27	CI
GT Biopharma, Inc. Announces CFO Changes	Jun. 07	CI
Top Midday Decliners	May. 21	MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	May. 21	MT
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	May. 21	AQ
Top Premarket Gainers	May. 20	MT
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 15	AQ
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	Mar. 26	AQ
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	Feb. 01	MT
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	Feb. 01	AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	Dec. 07	AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	Dec. 06	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	Dec. 04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News GT Biopharma, Inc. Euronext Paris

Equities

GTBP

US36254L3087

Summary

Filters